Smartphone-based Incentives Intervention to Increase Smoking Cessation During Pregnancy

ClinicalTrials.gov ID: NCT07840118

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07840118. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 12, 2026, 5:08 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Examining a Digital Perinatal Smoking-Cessation Intervention

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Cigarette smoking is the leading preventable cause of poor pregnancy outcomes in the U.S. and a problem for which more effective and easy-to-access treatments are much needed. This study examines whether outcomes achieved with recommended clinical practices (referral to state tobacco Quitline with follow-up and further referrals for those continuing to smoke) can be improved by also offering financial incentives delivered through a smartphone for maternal smoking abstinence.

Study identification

NCT ID: NCT07840118
Recruitment status: Not yet recruiting
Study type: Interventional
Phase: Not applicable
Lead sponsor: University of Vermont; Other
Enrollment: 137 participants

Conditions and interventions

Conditions

Interventions

Best Practices Behavioral
Financial Incentives Behavioral

Behavioral

Eligibility (public fields only)

Age range: 18 Years to 50 Years
Sex: Female
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 2026 (Estimated)
Primary completion: May 2028 (Estimated)
Completion: May 2028 (Estimated)
Last update posted: Sep 24, 2026

2026 – 2028

United States locations

U.S. sites: 1
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
University of Vermont	Burlington	Vermont	05464	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07840118, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 24, 2026 · Synced Nov 12, 2026